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Purpose. To compare the mucosal membrane transport of gabapentin
and pregabalin in animal small intestine.
Methods. Uptake of the two drugs by brush-border membrane
vesicles (BBMV) from rat and rabbit small intestine was studied as a
function of temperature, uptake-medium sodium content, and intes-
tinal region. Amino acid inhibition studies were conducted with
pregabalin.
Results. Gabapentin uptake by rat and rabbit jejunal BBMV was
sodium independent, whereas pregabalin uptake was sodium depen-
dent. Uptake of both drugs in rabbit small intestinal vesicles was
greater at 25°C than at 4°C in the absence of sodium and an addi-
tional increase in uptake was observed for pregabalin at 25°C in the
presence of sodium. Pregabalin uptake in rabbit duodenal, jejunal,
and ileal BBMV was equivalent, whereas gabapentin uptake was
greater in duodenal and ileal BBMV, compared with jejunal BBMV.
Although inhibition is weak, a decrease in BBMV uptake of pregaba-
lin is observed with coincubation of high concentrations of both neu-
tral and basic amino acids.
Conclusions. Amino acid carriers mediate the apical uptake of both
drugs in the small intestine. Although gabapentin and pregabalin are
structurally similar, their small intestinal mucosal uptake differs in
sodium dependence and region dependence. Gabapentin uptake is
likely mediated by system b0,+, whereas pregabalin uptake is also
mediated by B0 and/or B0,+.
KEY WORDS: gabapentin; pregabalin; intestinal absorption; mem-
brane vesicles.
INTRODUCTION
The gabapentenoids (three substituted GABA deriva-
tives) are under study for their clinical potential to treat a
number of diseases of the central nervous system as a function
of their anticonvulsant, antinociceptive, anxiolytic, and neu-
roprotective activity (1). Of this drug class, Neurontin (gaba-
pentin [GP]) is on the prescription market in tablet, capsule,
and liquid dosage forms, and Pregabalin (isobutyl GABA
[IBG]) is currently under FDA review as a capsule dosage
form (Fig. 1). Although these derivatives were initially syn-
thesized to increase g-amino butyric acid (GABA) lipophilic-
ity to passively permeate the blood-brain barrier, it has been
reported that their transport across this barrier is mediated by
the large neutral amino acid carrier, system L (2). Consistent
with saturation of carrier-mediated transport in other organ
systems, clinical studies with GP have shown dose-dependent
absorption, and intestinal uptake of GP was inhibited by sev-
eral large neutral amino acids (3). In a study comparing the
intestinal absorption of GP and IBG, cross-inhibition profiles
of these drugs were not consistent with transport by a single
carrier (4). The research reported in this follow-up commu-
nication was motivated by a recent study in canine small in-
testinal brush-border membrane vesicles (BBMV) showing
that uptake of the nitric oxide synthase inhibitor, NG-nitro-
L-arginine, is mediated by both sodium-dependent system




Unlabeled and C14-labeled GP (specific activity 4.3 mCi/
mmol) and IBG (specific activity 3.6 mCi/mmol) were sup-
plied by Pfizer, formerly Parke Davis/Warner Lambert.
Analysis of vesicle uptake of these drugs by measurement of
traced radiolabel is legitimized by the fact that these drugs are
not metabolized by rat, rabbit, or human (6). Candidate trans-
port inhibitors including L-phenylalanine, L-leucine, L-
methionine, L-lysine, L-arginine, L-proline, L-glycine, b-ala-
nine, g-amino butyric acid (GABA), glycyl L-proline, and
cephalexin were obtained from Sigma (St. Louis, MO). Man-
nitol, D-glucose, salts, and buffers as well as the alkaline phos-
phatase (ALP) and sodium-potassium ATPase assay kits
were also obtained from Sigma. The protein assay kit was
obtained from Bio-Rad (Richmond, CA). D-1-3H glucose
(specific activity 15.5 Ci/mmol), used to verify carrier-
mediated vesicle uptake, was obtained from New England
Nuclear (Boston, MA).
Intestinal Tissue
Rat jejunum was isolated as the first 40 cm of small in-
testine past the ligament of Trietz from anesthetized Sprague-
Dawley (Charles River Breeding Labs, Pearl River, NY) rats.
Rabbit intestine was obtained fresh from other laboratories
immediately after animal anesthesia and removal of other
organ systems. Most experiments were performed on jejunum
removed up to 75 cm from the ligament of Trietz. In the
regional studies, duodenum was obtained from the stomach
to the ligament of Trietz and ileum up to 50 cm from the
ileocecal junction. Typically, pooled jejunal samples from sev-
eral rats were required for uptake experiments comparing
treatments, whereas intestinal segments from one rabbit pro-
vided sufficient tissue for an equivalent number of treatment
variables.
BBMV Preparation and Characterization
Vesicle preparation procedures with intestinal tissue
were performed on ice or under refrigeration. Intestinal seg-
ments were washed with ice-cold saline, the mucosa was re-
moved by scraping with glass cover slides, and the tissue was
homogenized. Intestinal BBMV were prepared by the cal-
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cium precipitation method as described by Yuasa et al. (7).
Preparation protein determination for uptake normalization
was determined by using the Bio-Rad assay kit. Brush-border
membrane enrichment over intestinal mucosal homogenate
was determined by measuring alkaline phosphatase activity.
Uptake Experiments
BBMV overshoot uptake of 3H-D-glucose from 100 mM
D-glucose traced with 2 mCi/mL of radiolabel was used to
verify carrier-mediated vesicle uptake from incubation buffer
composed of 80 mM Hepes, 45 mM Tris, and 100 mM NaCl
adjusted to pH 7.5 and adjusted to isotonicity with mannitol.
Vesicle loading buffers and sodium-free incubation buffers
replaced NaCl with 100 mM of KCl and in some cases with
100 mM of choline chloride. Mannitol adjustment of isotonic-
ity was altered in studies using high concentrations of drug
uptake inhibitor candidates. Drug incubation concentrations
were 1 mM in rat BBMV and 200 mM in rabbit BBMV.
Uptake experiments were conducted by using a Millipore fil-
tration apparatus (Millipore Corp., Bedford, MA). Typically,
40 mL of uptake solution was rapidly mixed with 10 mL of
membrane vesicles (0.07–0.1 mg of protein). After incubation
for a selected time interval, uptake was stopped with an ice-
cold stop solution containing 100 mM mannitol, 100 mM KCl,
and 10 mM HEPES at pH 7.5. Stopped uptake mixtures were
filtered and washed with ice-cold stop buffer. Radioactivity
remaining on the filter was determined by using a Beckman
LS 6000 SC scintillation counter (Beckman Instruments, San
Jose, CA). All uptake measurements were corrected for non-
specific filter binding.
Data Analysis
Uptake values in the rat BBMV and rabbit BBMV inhi-
bition studies are mean values of duplicate uptake studies on
the same preparation. Uptake values in all other rabbit
BBMV studies are represented as the means ± SEM of three
rabbit preparations using the average of duplicate uptakes
from the same animal preparation. Significant differences be-
tween uptake values as a function of treatment variables are
determined by either Student’s t test or analysis of variance
(ANOVA) where appropriate. Statistically significant differ-
ences from controls were assessed at a 95% level by one-
factor ANOVA.
RESULTS
The specific activity of the brush-border marker enzyme,
alkaline phosphatase, was increased in the vesicle prepara-
tions over that of crude intestinal homogenate corresponding
to an enrichment factor of 13.7-fold in rat and 16.5-fold in
rabbit. Sodium-potassium ATPase was not enhanced in the
vesicle preparation (enrichment factor < 1 in both species),
indicating minimal contamination with basolateral mem-
branes. A characteristic overshoot phenomenon for the up-
take of D-glucose was evident in the presence of an inwardly
directed sodium gradient documenting the presence of func-
tional membrane vesicles in preparations from both species.
Previous studies showing carrier-mediated intestinal
transport of GP and IBG had been conducted in rat in situ
intestinal perfusions and in vitro intestinal tissue (3,4). In a
preliminary study to follow up this previous work in rats,
average uptake from a single pooled animal preparation was
determined as a function of incubation time using BBMV
made from rat jejunum. This study showed that 1 mM GP
uptake was sodium independent (Fig. 2a), whereas 1 mM IBG
uptake included a sodium-dependent component (Fig. 2b).
This study was repeated in rabbit jejunum using 200 mM drug
concentrations. Tissue from one rabbit is sufficient to conduct
region-dependent experiments that would require tissue from
6 to 10 rats. Similar to rats, jejunal uptake of GP was sodium
independent (Fig. 3a), whereas uptake of IBG included a
sodium-dependent component (Fig. 3b).
Comparing 30-s uptake at 4°C vs. 25°C in rabbit jejunal
BBMV, uptake of IBG (Fig. 4a) showed a greater increase
with temperature than did GP, and IBG uptake was signifi-
cantly lower than GP uptake at 4°C (Fig. 4b). As a function of
rabbit small intestinal region, IBG uptake at 30 s by BBMV
was region independent (Fig. 4a), whereas GP uptake was
lower in the jejunum than in the duodenum and ileum (Fig.
4b). In a single jejunal BBMV pregabalin uptake study, self-
inhibition of 200 mM 14C-labeled IBG by cold drug at 50 mM
reduced labeled drug uptake by only 50% in BBMV from
vesicle incubation solutions containing 100 mM of sodium
chloride at pH 7.5. For dipolar (neutral) amino acid inhibi-
tors, both 50 mM leucine and 50 mM phenylalanine as well as
50 mM GP reduced drug uptake by 35%, whereas 50 mM
methionine reduced drug uptake by 25%. For basic amino
acids, 50 mM arginine and 50 mM lysine reduced drug uptake
by 25% and 20%, respectively. IBG uptake was not reduced
by proline, glycine, GABA, glycyl L-proline, or cephalexin
(Table I). Inhibition data were obtained at 30 s of vesicle
incubation time.
DISCUSSION
Carrier-mediated transport was previously shown for
both GP (3,4) and IBG (4) in rat small intestine. Cross-
inhibition studies suggested that multiple amino acid trans-
port systems might be involved in the small intestinal absorp-
tion of these gabapentenoids (4). A recent study (5), showing
that both sodium-dependent and sodium-independent trans-
porters mediated small intestinal brush-border membrane up-
take of the nitric oxide synthase inhibitor, NG-nitro-L-
arginine (L-NNA), led to the research outlined in this short
communication. Despite their structural similarity, the results
presented here provide a clear indication that IBG uptake is
sodium dependent, whereas GP uptake does not depend on
medium sodium content in both rat and rabbit small intestinal
BBMV. The higher uptake values obtained for both drugs in
rat BBMV is partly due to the fivefold higher concentrations
used compared with rabbit.
Based on the fact that GP and IBG are zwitterionic at
intestinal pH, neutral amino acid carriers should mediate
their intestinal absorption. This projection is consistent with
previous inhibition studies (3,4). Although GP and IBG are
Fig. 1. Structures of Neurontin (Gabapentin [GP]) and Pregabalin
(Isobutyl GABA [IBG]).
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neutral amino acid-like drugs, another report has shown that
GP inhibited arginine transport in Caco-2 cell monolayers (8).
Intestinal carriers mediating the transport of neutral amino
acids include sodium-dependent B0 (ATB0) for neutral amino
acids, sodium-dependent B0,+ (ATB0,+) for neutral and basic
amino acids, sodium-independent b0,+ for neutral and basic
amino acids, sodium-independent L (LAT2) for neutral
amino acids, and y+L which mediates sodium-dependent
transport of neutral amino acids and sodium-independent
transport of basic amino acids (9). However, glycoprotein de-
pendence of b0,+, y+L, and LAT2, which are amino acid ex-
changers, indicate that y+L and LAT2 are associated with the
basolateral rather than brush-border membrane (10). This
localization is somewhat surprising for intestinal system L
because amino acid transport by LAT2 is enhanced by a pro-
ton gradient, a dependence that is typically observed for
brush-border transporters in line with low mucosal microcli-
mate pH (11).
In addition to determining uptake sodium dependence as
a function of small intestinal region, carrier-mediated uptake
was evaluated by studies conducted at 4°C and 25°C. Statis-
tically higher uptake was observed for both drugs at the
higher temperature; however, this was more dramatic for
IBG, which showed much lower uptake at 4°C than GP. Al-
though the differences at 4°C are consistent with a lower IBG
partition coefficient for passive membrane permeation (log
Fig. 2. (a) Gabapentin (GP) uptake as a function of time in rat jeju-
nal BBMV in the presence and absence of 100 mM of sodium chlo-
ride in isotonic incubation media. Incubation drug concentrations are
1 mM traced with 14C-GP. Uptake values are the average of duplicate
measurements in the same rat BBMV preparation. (b) Pregabalin
(IBG) uptake as a function of time in rat jejunal BBMV in the pres-
ence and absence of 100 mM of sodium chloride in isotonic incuba-
tion media. Incubation drug concentrations are 1 mM traced with
14C-IBG. Uptake values are the average of duplicate measurements
in the same rat BBMV preparation.
Fig. 3. (a) Neurontin (GP) uptake as a function of time in rabbit
jejunal BBMV in the presence and absence of 100 mM of sodium
chloride in isotonic incubation media. Incubation drug concentrations
are 200 mM traced with 14C-GP. Uptake values are shown as the
mean value of three rabbit BBMV preparations ± SEM using the
average of duplicate measurements in the each rabbit BBMV prepa-
ration. (b) Pregabalin (IBG) uptake as a function of time in rabbit
jejunal BBMV in the presence and absence of 100 mM of sodium
chloride in isotonic incubation media. Incubation drug concentrations
are 200 mM traced with 14C-IBG. Uptake values are shown as the
mean value of three rabbit BBMV preparations ± SEM using the
average of duplicate measurements in each rabbit BBMV prepara-
tion.
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Kp −1.10 for GP and −1.35 for IBG), the 4°C differences are
larger than might be expected. The possibility that sodium-
independent amino acid exchangers might be less sensitive to
temperature than sodium-dependent amino acid cotransport-
ers could explain the 4°C data, but there is no literature evi-
dence for this.
Previous in vitro and in situ studies in rat intestine indi-
cated that cross-inhibition between neutral amino acids, leu-
cine, and phenylalanine, and these two gabapentenoids was
weak. Weak inhibition of 14C-IBG at 50 mM inhibitor con-
centration is also observed in these BBMV studies. Self-
inhibition of labeled IBG is only 50%; inhibition by neutral
amino acids and GP is only 25–35% and by basic amino acids
only 20–25%. The possibility that system B0 is partially in-
volved in IBG transport might explain the slightly higher in-
hibition by neutral compared to basic amino acids.
Previous studies on rabbit small intestinal transport of
neutral and basic amino acids indicated that transport in-
creased from proximal jejunum to distal ileum, whereas trans-
port was optimal in rat distal jejunum and proximal ileum and
optimal in the distal jejunum in human BBMV (12). Re-
gional-dependent studies were conducted here to determine
possible differences in uptake of these drugs by sodium-
dependent and sodium-independent systems in rabbit
BBMV. Although IBG uptake was region-independent, jeju-
nal uptake of GP was observed to be lower compared with
duodenum and ileum at both temperatures and in the pres-
ence or absence of a sodium gradient. For GP, the data sug-
gest that b0,+ transport is weaker in rabbit jejunum than other
regions of the small intestine and that this difference is evi-
dent even at the lower temperature for this amino acid ex-
changer. However, region-independent uptake is observed
for IBG in the absence of sodium, a condition under which
b0,+ would be projected to dominate IBG uptake. One expla-
nation for the fact that IBG transport is region independent
regardless of temperature and medium sodium conditions,
would be that entry of IBG into the vesicles by any pathway
provides for stronger trans-stimulation of jejunal b0,+ ex-
change uptake than is the case for GP.
Species differences in the distribution and regulation of
amino acid transport activity in the small intestine may limit
implications of this animal data for human absorption of the
gabapentenoids. For example, a recent study reports that leu-
cine transport in human small intestinal BBMV is primarily
mediated by B0, whereas in rabbit, leucine transport also con-
tains a small b0,+ component (13). However, the intestinal
transport differences between these structurally similar com-
pounds are intriguing. Given that these compounds are not
metabolized or protein bound in most species (6), the data
provided here suggest that differences in transport of the two
gabapentenoids by amino acid carriers could provide differ-
ences in pharmacokinetic profiles for oral absorption, organ
distribution, and renal elimination. Individual absorption dif-
ferences for IBG could be of particular importance because
B0,+ activity has recently been suggested to be a strong func-
tion of diet (5,14).
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Table I. Inhibition of 200 mM Pregabalin (IBG) Uptake in a Single
Rabbit Small Intestinal BBMV Preparation
Inhibitor
Percent Inhibition









Note. L-proline, L-glycine, b-alanine, g-amino butyric acid (GABA),
glycyl L-proline and cephalexin did not inhibit pregabalin uptake.
Fig. 4. (a) Means ± SEM pregabalin (IBG) uptake as a function of
temperature, sodium-gradient, and intestinal region in rabbit small
intestinal BBMV. Incubation drug concentrations are 200 mM traced
with 14C-IBG. Uptake at 25°C is statistically greater than at 4°C, and
uptake in the presence of a sodium gradient is statistically greater
than in the absence of a sodium gradient in each intestinal region. (b)
Means ° SEM gabapentin (GP) uptake as a function of temperature,
sodium-gradient, and intestinal region in rabbit small intestinal
BBMV. Incubation drug concentrations are 200 mM traced with 14C-
GP. Uptake at 25°C is statistically greater than at 4°C in each intes-
tinal region. Uptake in the jejunal BBMV is statistically lower than in
duodenal and ileal BBMV at both temperatures and in the presence
or absence of sodium.
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